Melanoma and additional primary cancers

Melanoma Research

Volumn 10, Issue 2, 2000, Pages 145-152

  Retsas, S ^a   Mohith, A ^a   Bell, J ^b   Horwood, N ^a   Alexander, H ^a  

^a IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^b Thames Cancer Registry   (United Kingdom)

Author keywords

Additional cancers; Aetiology; Chemotherapy; Melanoma; Multiple neoplasms; Survival

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER INCIDENCE; CANCER REGISTRY; CANCER RISK; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HUMAN; KIDNEY CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTIPLE CANCER; MYELODYSPLASIA; PRIORITY JOURNAL; UNITED KINGDOM;

EID: 0034062943     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200010020-00007     Document Type: Article

References (23)

1. 1. Coleman CN, Tucker MA. Secondary cancers. In: De Vita VT Jr, Hellman S, Rosenberg SA, eds. Cancer, Principles and Practice of Oncology, 3rd edn, Philadelphia: JB Lippincott, 1989: 2181-2190.
2. 2. Retsas S, Quigley M, Pectasides D, MacRae K, Henry K. Clinical and histologic involvement of regional lymph nodes in malignant melanoma: adjuvant vindesine improves survival. Cancer 1994; 73: 2119-2130.
3. 3. Retsas S, Mohith A, Macrae K, Henry K. Adjuvant vindesine in malignant melanoma: 20 years on. Melanoma Res 1997; 7: 163.
4. 4. Retsas S, Mackenzie H, Mohith A. Fertility after prolonged chemotherapy for metastatic malignant disease. Lancet 1996; 347: 687.
5. 5. Retsas S, Bayliss M, Sheikh N, Chong SL, Bafaloukos D. Chemotherapy of malignant melanoma: the European experience. Rev Med Int 1990; suppl XI: 51-58.
6. 6. Retsas S. Strategies for improving survival in malignant melanoma: focus on vindesine. J Drug Dev Clin Pract 1995; 7: 159-171.
7. 7. Retsas S, Mohith A, Mackenzie H. Taxol and Vinorelbine: a new active combination for disseminated malignant melanoma. Anticancer Drugs 1996; 2: 161-165.
8. 8. Retsas S. Systemic treatment of malignant melanoma: grade is as important as stage. Clin Exp Dermatol 1997; 22: 67-71.
9. 9. van Leeuwen FE. Second cancers: methods of assessing second cancer risk. In: De Vita VT Jr, Hellman S, Rosenberg SA, eds. Cancer, Principles and Practice of Oncology, 5th edn, Philadelphia: Lippincott-Raven, 1997.
10. 10. Parkin DM, Muir CS, Whelan SL, Gao YT, Ferlay J, Powell J, eds. Cancer Incidence in Five Continents, vol VI. IARC Scientific Publications No. 120. Lyon: IARC, 1992.
11. 11. Horwich A, Bell J. Mortality and cancer incidence following radiotherapy for seminoma of the testis. Radiother Oncol 1994; 30: 193-198.
12. 12. Kaldor JM, Day NE, Petterson F, Clarke EA, Pedersen D, et al. Leukemia following chemotherapy for ovarian cancer. N Engl J Med 1990; 322: 1-6.
13. 13. Gardner MJ, Altman DG. Statistics with Confidence. London: British Medical Journal, 1989.
14. 14. Boland SL, Shaw HM, Milton GW. Multiple primary cancers in patients with malignant melanoma. Med J Aust 1976; 1(15): 517-519.
15. 15. Tucker MA, Boice JD Jr, Hoffman DA. Second cancer following cutaneous melanoma and cancers of the brain, thyroid, connective tissue, bone and eye in Connecticut, 1935-82. Natl Cancer Inst Monogr 1985; 68: 161-189.
16. 16. Levi F, La Vechia C, Randimbison L, Te VC, Erler G. Incidence of invasive cancers following cutaneous melanoma. Int J Cancer 1997; 72(5): 776-779.
17. 17. Greene MH, Hoover RN, Fraumeni JF Jr. Subsequent cancer in patients with chronic lymphocytic leukaemia - a possible immunologic mechanism. J Natl Cancer Inst 1978; 61(2): 337-340.
18. 18. Osterlind A, Olsen JH, Lynge E, Ewertz M. Second cancers following cutaneous melanoma and cancers of the brain, thyroid, connective tissue, bone and eye in Denmark, 1943-80. Natl Cancer Inst Monogr 1985; 68: 361-388.
19. 19. Travis LB, Curtis RE, Boice JD Jr, Hankey BF, Fraumeni JF Jr. Second cancers following non-Hodgkin's lymphoma. Cancer 1991; 67(7): 2002-2009.
20. 20. Harvey EB, Brinton LA. Second cancer following cancer of the breast in Connecticut. Natl Cancer Inst Monogr 1985; 68: 99-112.
21. 21. Swerdlow AJ, Storm HH, Sasieni PD. Risks of second primary malignancy in patients with cutaneous and ocular melanoma in Denmark, 1943-1989. Int J Cancer 1995; 61(6): 773-779.
22. 22. Wassberg C, Thorn N, Yuen J, Ringborg U, Hakulinen T. Second primary cancers in patients with cutaneous malignant melanoma. Br J Cancer 1996; 73(2): 255-259.
23. 23. Burden AD, Vestey JP, Sirel JM, Aitchison TC, Hunter JAA, MacKie RM. Multiple primary melanoma: risk factors and prognostic implications. BMJ 1994; 309: 375